Oligonucleotide Therapies: The Past and the Present

Human Gene Therapy

Volumn 26, Issue 8, 2015, Pages 475-485

  Lundin, Karin E ^a   Gissberg, Olof ^a   Smith, C I Edvard ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGODEOXYNUCLEOTIDE; APTAMER; GUANINE QUADRUPLEX; MICRORNA; NUCLEIC ACID; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TRIPLEX FORMING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE;

ANTISENSE THERAPY; BASE PAIRING; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HISTORY OF MEDICINE; HOOGSTEEN BINDING; HUMAN; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RNA DEGRADATION; RNA SPLICING; SPLICE SWITCHING; ANIMAL; GENE THERAPY; GENETICS; HISTORY; RNA INTERFERENCE; RNA STABILITY; SYNTHESIS;

ANIMALS; GENETIC THERAPY; HISTORY, 20TH CENTURY; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA STABILITY;

EID: 84939802078     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.070     Document Type: Review

References (148)

1. Avery OT, Macleod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from Pneumococcus type III. J Exp Med 1944;79:137-158.
2. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171:737-738.
3. Reist EJ, Benitez A, Goodman L. The synthesis of some 5'-thiopentofuranosylpyrimidines. J Org Chem 1964;29:554-558.
4. Codington JF, Doerr IL, Fox JJ. Nucleosides. XVIII. Synthesis of 2-fluorothymidine, 2-fluorodeoxyuridine, and other 2-halogeno-2-deoxy nucleosides. J Org Chem 1964;29:558-564.
5. Eckstein F. Nucleoside phosphorothioates. J Am Chem Soc 1966;88:4292-4294.
6. Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006;16:169-180.
7. Geary RS, Norris D, Yu R, et al. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 2015. [Epub ahead of print]
8. Bobst AM, Rottman F, Cerutti PA. Effect of the methylation of the 2-hydroxyl groups in polyadenylic acid on its structure in weakly acidic and neutral solutions and on its capability to form ordered complexes with polyuridylic acid. J Mol Biol 1969;46:221-234.
9. Field AK, Tytell AA, Lampson GP, et al. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 1967;58:1004-1010.
10. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
11. Tokunaga T, Yamamoto H, Shimada S, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984;72: 955-962.
12. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
13. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745.
14. Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol 2015;109:141211-141210.
15. Skold AE, Hasan M, Vargas L, et al. Singlestranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 2012;120:768-777.
16. Hoogsteen K. The crystal and molecular structure of a hydrogen-bonded complex between 1-methylthymine and 9-methyladenine. Acta Cryst 1963;16:907-916.
17. Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009;86:151-164.
18. Moser HE, Dervan PB. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 1987;238:645-650.
19. Le Doan T, Perrouault L, Praseuth D, et al. Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-[alpha]-thymidylate covalently linked to an azidoproflavine derivative. Nucleic Acids Res 1987; 15:7749-7760.
20. Khorana HG, Agarwal KL, Buchi H, et al. Studies on polynucleotides. 103 Total synthesis of the structural gene for an alanine transfer ribonucleic acid from yeast. J Mol Biol 1972;72: 209-217.
21. Sinha ND, Biernat J, McManus J, et al. Polymer support oligonucleotide synthesis XVIII: use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucleic Acids Res 1984;12:4539-4557.
22. Usman N, Ogilvie KK, Jiang MY, et al. Automated chemical synthesis of long oligoribonucleotides. J Am Chem Soc 1987;109:7845-7854.
23. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-284.
24. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978;75:285-288.
25. Donis-Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res 1979;7:179-192.
26. Walder JAIC, Walder RY (inventor), University of Iowa Research Foundation (assignee). Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved. 1995.
27. ISIS Pharmaceuticals (assignee). Application number US 08/861,306. Filed 1991.
28. Cook PD (inventor), ISIS Pharmaceuticals, Inc. (assignee). Gapped 2-modified oligonucleotides, Application number US 58564551999.
29. Stirchak EP, Summerton JE, Weller DD. Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res 1989;17:6129-6141.
30. Nielsen PE, Egholm M, Berg RH, et al. Sequenceselective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991;254:1497-1500.
31. Obika S, Nanbu D, Hari Y, et al. Synthesis of 2-O,4-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed C3-endo sugar puckering. Tetrahedron Lett 1997;38:8735-8738.
32. Koshkin AA, Singh SK, Nielsen P, et al. Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 1998;54:3607-3630.
33. Lundin KE, Hojland T, Hansen BR, et al. Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet 2013;82:47-107.
34. Ge R, Heinonen JE, Svahn MG, et al. Zorro locked nucleic acid induces sequence-specific gene silencing. FASEB J 2007;21:1902-1914.
35. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 2011;18:1111-1120.
36. Renneberg D, Leumann CJ. Watson-Crick basepairing properties of tricyclo-DNA. J Am Chem Soc 2002;124:5993-6002.
37. Goyenvalle A, Griffith G, Babbs A, et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 2015;21:270-275.
38. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-510.
39. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-822.
40. Bielinska A, Shivdasani RA, Zhang LQ, et al. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250:997-1000.
41. Gray AW. Modeling, synthesis, and hybridization properties of (L)-ribonucleic acid. J Am Chem Soc 1992;114:9731-9736.
42. Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer- therapeutics. Drug Discov Today 2015;20:147-155.
43. Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 1993; 90:8673-8677.
44. Bayever E, Iversen PL, Bishop MR, et al. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 1993;3:383-390.
45. Fomivirsen approved for CMV retinitis: first antisense drug. AIDS Treat News 1998:7.
46. Halperin SA, Van Nest G, Halperin B, et al. Immunostimulatory Oligonucleotide (ISS ODN) Co-Injection Enhances Protective Antibody Response to Hepatitis B Surface Antigen (HBsAg) and Is Well-Tolerated by Seronegative Individuals. Presented in part at the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society of Microbiology, Chicago, IL, 2001.
47. Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003;21:2461-2467.
48. Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351: 2805-2816.
49. Ruckman J, Green LS, Beeson J, et al. 2-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-20567.
50. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
51. ClinicalTrials.gov. 2005. Safety and efficacy study of small interfering ribonucleic acid (RNA) molecule (Cand5) to treat wet age-related macular degeneration. https://clinicaltrials.gov/ct2/show/NCT00259753?term=bevasiranib&rank=5.
52. Singerman L. Combination therapy using the small interfering RNA bevasiranib. Retina 2009;29: S49-S50.
53. Kleinman ME, Yamada K, Takeda A, et al. Sequenceand target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591-597.
54. Ozcan G, Ozpolat B, Coleman RL, et al. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015. [Epub ahead of print]; doi: 10.1016/j.addr.2015.01.007.
55. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357:2677-2686.
56. Disterer P, Kryczka A, Liu Y, et al. Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 2014;25:587-598.
57. Hildebrandt-Eriksen ES, Bagger YZ, Knudsen TB, et al. A unique therapy for HCV inhibits micro-RNA-122 in humans and results in HCV RNA suppression in chronically infected chimpanzees: results from primate and first-in-human studies. Hepatology 2009;50 Suppl:228A.
58. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting micro-RNA. N Engl J Med 2013;368:1685-1694.
59. DeYoung C. Mirna Therapeutics presents interim phase 1 data on first-in-class microRNA-34 mimic, MRX34. 2014. www.mirnarx.com/pdfs/releases/2014%201119%20Mirna%20EORTC-AACR.pdf (accessed on July 28, 2015).
60. JinekM, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337:816-821.
61. Farooqi AA, Rehman ZU, Muntane J. Antisense therapeutics in oncology: current status. Onco Targets Ther 2014;7:2035-2042.
62. Evers MM, Toonen LJ, van Roon-Mom WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 2015. [Epub ahead of print]; doi:10.1016/j.addr.2015.03.008.
63. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012;19:60-71.
64. Martinez T, Wright N, Lopez-Fraga M, et al. Silencing human genetic diseases with oligonucleotidebased therapies. Hum Genet 2013;132:481-493.
65. Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 1990;20:259-267.
66. Fluiter K, Mook OR, Vreijling J, et al. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer. Mol Biosyst 2009;5:838-843.
67. Chauhan NB, Siegel GJ. Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. Neuroscience 2007;146:143-151.
68. Hu J, Matsui M, Gagnon KT, et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009;27:478-484.
69. Gagnon KT, Pendergraff HM, Deleavey GF, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 2010;49:10166-10178.
70. Sun X, Marque LO, Cordner Z, et al. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum Mol Genet 2014;23:6302-6317.
71. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003;100:7195-7200.
72. Ostergaard ME, Southwell AL, Kordasiewicz H, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 2013;41:9634-9650.
73. Bramsen JB, Kjems J. Development of therapeutic-grade small interfering RNAs by chemical engineering. Front Genet 2012;3:154.
74. Bramsen JB, Laursen MB, Damgaard CK, et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007;35:5886-5897.
75. Turunen MP, Lehtola T, Heinonen SE, et al. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ Res 2009;105:604-609.
76. Liu J, Pendergraff H, Narayanannair KJ, et al. RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucleic Acids Res 2013; 41:8788-8801.
77. Hu J, Liu J, Narayanannair KJ, et al. Alleleselective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry 2014;53:4510-4518.
78. Westerlind U, Westman J, Tornquist E, et al. Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine. Glycoconj J 2004;21:227-241.
79. Lonnberg H. Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics. Bioconjug Chem 2009;20:1065-1094.
80. Rajeev KG, Nair JK, Jayaraman M, et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem 2015;16:903-908.
81. Juliano RL, Ming X, Carver K, et al. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther 2014;24:101-113.
82. Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011;29:341-345.
83. El Andaloussi S, Lakhal S, Mager I, et al. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev 2013;65:391-397.
84. Kanazawa T, Akiyama F, Kakizaki S, et al. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 2013;34:9220-9226.
85. Aaldering LJ, Tayeb H, Krishnan S, et al. Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy. RNA Biol 2015;12:412-425.
86. Colombo S, Zeng X, Ragelle H, et al. Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. Expert Opin Drug Deliv 2014;11:1481-1495.
87. Lorenzer C, Dirin M, Winkler AM, et al. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015;203:1-15.
88. Piascik P. Fomiversen sodium approved to treat CMV retinitis. J Am Pharm Assoc (Wash) 1999;39: 84-85.
89. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006.
90. Shan Y, Zheng J, Lambrecht RW, et al. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007;133:1166-1174.
91. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ''antagomirs.'' Nature 2005;438:685-689.
92. Piva R, Spandidos DA, Gambari R. From micro-RNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 2013;43:985-994.
93. Poltronieri P, D'Urso PI, Mezzolla V, et al. Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours. Chem Biol Drug Des 2013;81:79-84.
94. Lukiw WJ. NF-kappaB-regulated, proinflammatory miRNAs in Alzheimer's disease. Alzheimers Res Ther 2012;4:47.
95. McGregor RA, Choi MS. microRNAs in the regulation of adipogenesis and obesity. Curr Mol Med 2011;11:304-316.
96. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-865.
97. Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve 2000;23:1456-1471.
98. Porensky PN, Burghes AH. Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum Gene Ther 2013;24:489-498.
99. Khoo B, Krainer AR. Splicing therapeutics in SMN2 and APOB. Curr Opin Mol Ther 2009;11:108-115.
100. Bestas B, Moreno PM, Blomberg KE, et al. Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest 2014;124:4067-4081.
101. Bestas B, Turunen JJ, Blomberg KE, et al. Splicecorrection strategies for treatment of x-linked agammaglobulinemia. Curr Allergy Asthma Rep 2015;15:510.
102. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989;45:498-506.
103. Koo T, Wood MJ. Clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy. Hum Gene Ther 2013;24:479-488.
104. Kollberg G, Holme E. Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy. Neuromuscul Disord 2009;19:833-836.
105. Sanaker PS, Toompuu M, McClorey G, et al. Antisense oligonucleotide corrects splice abnormality in hereditary myopathy with lactic acidosis. Gene 2012;494:231-236.
106. Palhais B, Praestegaard VS, Sabaratnam R, et al. Splice-shifting oligonucleotide (SSO) mediated blocking of an exonic splicing enhancer (ESE) created by the prevalent c.903 + 469T > C MTRR mutation corrects splicing and restores enzyme activity in patient cells. Nucleic Acids Res 2015. [Epub ahead of print]; doi: 10.1093/nar/gkv275
107. El-Andaloussi S, Johansson HJ, Lundberg P, et al. Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 2006;8:1262-1273.
108. Moreno PM, Wenska M, Lundin KE, et al. A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins and nucleic acids. Nucleic Acids Res 2009;37:1925-1935.
109. Hammond SM, McClorey G, Nordin JZ, et al. Correlating in vitro splice switching activitywith systemic in vivo delivery using novel ZEN-modified oligonucleotides. Mol Ther Nucleic Acids 2014;3:e212.
110. Zammarchi F, de Stanchina E, Bournazou E, et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci USA 2011;108:17779-17784.
111. Nielsen TO, Sorensen S, Dagnaes-Hansen F, et al. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. Br J Cancer 2013;108:2291-2298.
112. Rocha CS, Wiklander OP, Larsson L, et al. RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. J Mol Cell Cardiol 2015;82:186-193.
113. Singh NK, Singh NN, Androphy EJ, et al. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006;26:1333-1346.
114. Hua Y, Vickers TA, Okunola HL, et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008;82:834-848.
115. Walke DW. Isis Pharmaceuticals reports interim results from ISIS-SMN Rx multiple dose study in children with spinal muscular atrophy. 2014. ir.isispharm.com/phoenix.zhtml?c=222170&p=irolnewsArticle&ID=1902197 (accessed on July 28, 2015).
116. Skordis LA, Dunckley MG, Yue B, et al. Bifunctional antisense oligonucleotides provide a transacting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 2003;100:4114-4119.
117. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003;10:120-125.
118. Brosseau JP, Lucier JF, Lamarche AA, et al. Redirecting splicing with bifunctional oligonucleotides. Nucleic Acids Res 2014;42:e40.
119. Echigoya Y, Yokota T. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 2014;24:57-68.
120. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Med Oncol 2007;24:189-196.
121. Bestas B, McClorey G, Tedebark U, et al. Design and application of bispecific splice-switching oligonucleotides. Nucleic Acid Ther 2014;24:13-24.
122. Zhou J, Rossi JJ. Cell-type-specific, aptamerfunctionalized agents for targeted disease therapy. Mol Ther Nucleic Acids 2014;3:e169.
123. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-132.
124. Pastor F, Kolonias D, Giangrande PH, et al. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010;465:227-230.
125. Zhou J, Neff CP, Swiderski P, et al. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 2013;21:192-200.
126. Ni X, Zhang Y, Ribas J, et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011;121:2383-2390.
127. Kotula JW, Pratico ED, Ming X, et al. Aptamermediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther 2012;22:187-195.
128. Pofahl M, Wengel J, Mayer G. Multifunctional nucleic acids for tumor cell treatment. Nucleic Acid Therapeutics 2014;24:171-177.
129. Gellert M, Lipsett MN, Davies DR. Helix formation by guanylic acid. Proc Natl Acad Sci USA 1962;48:2013-2018.
130. Yaswen P, Stampfer MR, Ghosh K, et al. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 1993;3:67-77.
131. Dapic V, Bates PJ, Trent JO, et al. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 2002;41:3676-3685.
132. Cannata F, Brunet E, Perrouault L, et al. Triplexforming oligonucleotide-orthophenanthroline conjugates for efficient targeted genome modification. Proc Natl Acad Sci USA 2008;105:9576-9581.
133. Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet 2013;14:880-893.
134. Nielsen PE. Sequence-selective targeting of duplex DNA by peptide nucleic acids. Curr Opin Mol Ther 2010;12:184-191.
135. Paramasivam M, Cogoi S, Filichev VV, et al. Purine twisted-intercalating nucleic acids: a new class of anti-gene molecules resistant to potassium-induced aggregation. Nucleic Acids Res 2008;36:3494-3507.
136. Boulware SB, Christensen LA, Thames H, et al. Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog 2014;53:744-752.
137. Lundin KE, Good L, Stromberg R, et al. Biological activity and biotechnological aspects of peptide nucleic acid. Adv Genet 2006;56:1-51.
138. Bentin T, Nielsen PE. Superior duplex DNA strand invasion by acridine conjugated peptide nucleic acids. J Am Chem Soc 2003;125:6378-6379.
139. Lundin KE, Hasan M, Moreno PM, et al. Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored ''Bioplex'' formation. Biomol Eng 2005;22:185-192.
140. Ge R, Svahn MG, Simonson OE, et al. Sequence-specific inhibition of RNA polymerase III-dependent transcription using Zorro locked nucleic acid (LNA). J Gene Med 2008;10: 101-109.
141. Zaghloul EM, Madsen AS, Moreno PM, et al. Optimizing anti-gene oligonucleotide ''Zorro-LNA'' for improved strand invasion into duplex DNA. Nucleic Acids Res 2011;39:1142-1154.
142. Ling JQ, Hou A, Hoffman AR. Long-range DNA interactions are specifically altered by locked nucleic acid-targeting of a CTCF binding site. Biochim Biophys Acta 2011;1809: 24-33.
143. Beane R, Gabillet S, Montaillier C, et al. Recognition of chromosomal DNA inside cells by locked nucleic acids. Biochemistry 2008;47: 13147-13149.
144. Egholm M, Christensen L, Dueholm KL, et al. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. Nucleic Acids Res 1995;23:217-222.
145. Moreno PM, Geny S, Pabon YV, et al. Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. Nucleic Acids Res 2013;41: 3257-3273.
146. Lonkar P, Kim KH, Kuan JY, et al. Targeted correction of a thalassemia-associated betaglobin mutation induced by pseudo-complementary peptide nucleic acids. Nucleic Acids Res 2009;37:3635-3644.
147. Kayali R, Bury F, Ballard M, et al. Site-directed gene repair of the dystrophin gene mediated by PNA-ssODNs. Hum Mol Genet 2010;19: 3266-3281.
148. Juliano RL, Carver K. Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev 2015.